Korean J Hematol.
1999 Feb;34(1):157-162.
A Case of Cerebral Syndrome Associated with High-Dose Cytosine Arabinoside Chemotherapy
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea.
Abstract
- Cytosine arabinoside (Ara-C) is a highly active agent in the treatment of acute leukemia and malignant lymphoma. The use of high-dose Ara-C therapy has been advanced as a possible means of overcoming resistance. High dose Ara-C regimens are occasionally associated with cerebellar and cerebral toxicities while toxicities in conventional dose regimens are mainly restricted to the bone marrow and gastrointestinal tract. A 21-year-old male patient with acute lymphoblastic leukemia in second relapse developed cerebral syndrome 10 days after high-dose Ara-C chemotherapy. We present a case of acute cerebral toxicity after high dose Ara-C chemotherapy with relevant literature review.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of Acute Myelogenous Leukemia in Children: Remission Induction with Adriamycin and Cytosine Arabinoside, and Postremission Maintenance Chemotherapy with Adriamycin, Cytosine Arabinoside and 6-thioguanine
- A Case of High Dose Cytosine Arabinoside Induced Stevens-Johnson Syndrome in a Patient with Malignant Lymphoma
- High-Dose Cytosine Arabinoside (HD Ara-C) Therapy for Refractory Acute Leukemia in Children
- Phase I clinical trial of simultaneous administration of intraperitoneal carboplatin, etoposide and cytosine arabinoside for refractory ovarian carcinoma
- Renission induction chemotherapy with idarubicin and cytosine arabinoside for the patients with acute myelogenous leukemia
